MedTrace Logo

The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension

NCT03722524 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1247

Last updated 2021-06-10

Study results available
· View outcomes & findings →

Summary

The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy.

The main aim of this study to assess the antihypertensive effectiveness effect on the 24-hour BP profile, as well as tolerability of and compliance to the treatment with a triple FDC of amlodipine / indapamide / perindopril arginine in hypertensive patients in the real clinical practice.

Type of program: Multicenter, observational, non-controlled, open-label program.

Investigators: Cardiologists and outpatient (primary care) physicians (general practitioners).

Number of patients: 1,300 hypertensive patients.

Conditions

  • Arterial Hypertension

Interventions

DRUG

amlodipine / indapamide / perindopril arginine FDC

CCB / diuretic / ACE inhibitor

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Principal Investigators

  • Natatya LOGUNOVA

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-07-17
Completion
2019-07-17

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03722524 on ClinicalTrials.gov